Back to today’s briefing

Story perspectives

IO Biotech's Cancer Vaccine Trial Fails, Stock Plummets 20%

8/11/2025

33 4

Summary

Story summary

IO Biotech's promising cancer vaccine, Cylembio, faced a setback in its Phase 3 melanoma trial, falling just short of its main goal, leading to a 20% plunge in stock prices. Undeterred, the company is pursuing FDA approval, highlighting encouraging results in specific patient groups, as it strives to carve out a niche in the crowded immunotherapy landscape.

1 of 1

Story summary

IO Biotech's promising cancer vaccine, Cylembio, faced a setback in its Phase 3 melanoma trial, falling just short of its main goal, leading to a 20% plunge in stock prices. Undeterred, the company is pursuing FDA approval, highlighting encouraging results in specific patient groups, as it strives to carve out a niche in the crowded immunotherapy landscape.